Advanced hepatocellular carcinoma

Brisk: A randomized, double blind, multi-center phase III study of Brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to Sorafenib.

• Phase III study
• Selection criteria

Intermediate stage HCC

Space: A phase II randomized, double-blind, placebo-contolled study of sorafenib or placebo in combination with transarterial chemoembolization (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC).

• Phase II study
• Selection criteria

Advanced Disease

A randomized discontinuation study of Brivanib alaninate (BMS-582664) versus Placebo in Subjets with advanced tumors.

• Study Phase II
• Gesloten voor pancreas, blaas, maag en slokdarm
• Selection criteria

Colon cancer: stage III and IV

Exploration of patients with Stage 3 Colon Cancer or Metastatic Colorectal Cancer Treated with oral Capecitabine.

• Study Phase II
• Selection criteria

Gist tumoren

An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after Ro -resection.

• Study Phase III
• Selection criteria

Colorectal 

An Obsevational study to evaluate whether the reimbursement conditions are met for Erbitux prescribed by oncologists/gastro-enterologists in patients with EGFR positive metastatic colorectal cancer in Belgium.

• Observationele studie
• Selection criteria

Advanced oesophageal cancer, locally or metastatic

Activity of sunitinib in esophageal cancer, melanoma and sarcoma. SEMS VUB08001 Investigation of candidate predictive biomarkers for efficacy of sunitinib malate in patients with advanced oesophageal cancer, melanoma and sarcoma. Translational subprotocol.

• Study Phase II
• Selection criteria

Advanced gastric adenocarcinoom

• Study Phase III
• Voorlopig inclusiestop
• Selection criteria